有机硅改性丙烯酸树脂性能研究

通过丙烯酸树脂与有机硅中间体接枝反应,制备了耐化学性好、附着力强、耐候性优异、透水气性好的有机硅改性丙烯酸树脂,研究了配方和工艺对其性能的影响、     

数码提花织物的组合全显色结构设计

由于分层组合设计模式下提花织物的结构特征和结构设计方法是数码提花织物产品创新设计的关键,为此介绍一种提花织物特有的组合织物结构设计方法。其设计原理是先在基本组织上设置全显色技术点,再进行全息组织设计,这样通过组合2个不同组织库中的组织,设计所得的组合织物结构具有不遮盖全显色的特点。该方法可用于设计各种组织循环的全息组织和建立相应的组织库,设计的数码提花织物结构稳定,可以表现细腻的彩色影光效果,另外,织物中并列排列的纱线数为偶数。     

硝胺推进剂用聚合物键合剂的研究进展

综述了硝胺推进剂产生"脱湿"现象的原因及改善力学性能的方法,介绍了目前国内外用于改善硝胺推进剂力学性能的三种聚合物键合剂的作用机理和效果。     

环氧丙烯酸树脂的合成及其改性

采用丙烯酸(AA)对环氧树脂(EP)进行光活性改性制备环氧丙烯酸树脂(EA),通过单因素试验法优选出制备EA的最佳反应条件。结果表明:制备EA的最佳反应条件是以N′N-二甲基苯胺为催化剂,w(催化剂)=2.5%(相对于反应物总质量而言);以对苯二酚为阻聚剂,w(阻聚剂)=0.1%(相对于反应物总质量而言);反应温度为90℃,反应时间为2.0～3.5h。当w(引发剂)=1.0%时,EA的固化性能较好。采用多元醇先对EP进行改性,然后再进行光活性改性,可明显降低产物的黏度。     

马来松香/SiO2杂化材料的研究

采用溶胶-凝胶法,以正硅酸乙酯（TEOS）为原料,制备硅溶胶;松香与马来酸酐熔融加成反应,生成马来松香;在对甲苯磺酸催化作用下,硅溶胶与马来松香发生酯化反应,生成马来松香／SiO2杂化材料。产物酸值较松香明显降低;FT-IR结果表明,其组份间以Si-O-C键键合;XRD结果表明,其为非晶态;DSC结果表明,其玻璃化转变温度㈣随着SiO2含量的增大而上升。     

保心包贴膜对稳定型心绞痛患者血浆内皮素和一氧化氮水平的影响

目的 研究保心包贴膜对稳定型心绞痛(SAP)患者血浆内皮素(ET)和一氧化氮(NO)水平的影响。方法 76例SAP患者随机单盲分为保心包组和硝酸异山梨酯组,分别给予保心包贴膜外敷心前区,每片4d(首次2片),共6片20d;硝酸异山梨酯10mg,每日3次,po。观察治疗前后血浆ET和NO水平。结果 SAP患者治疗前血浆ET和NO水平分别显著高于和低于正常对照组(均P<0.01);治疗后保心包组和硝酸异山梨酯组ET和NO代谢失衡均显著改善,但以保心包组改善更为显著(P<0.05)。结论 保心包贴膜显著改善SAP患者ET和NO的代谢失衡,可能是其有效缓解心绞痛的机理之一。     

冶金级硅吹Ar-H2O混合气精炼除

通过吹高纯氩气和水蒸汽混合气体的方法除去冶金级硅中的杂质磷。采用自行设计的吹气精炼装置,研究喷嘴类型、精炼时间、精炼温度、精炼气温度、精炼气流速等因素对除磷效果的影响。研究表明：使用侧壁和底部多孔型喷嘴,精炼时间3 h,精炼温度1793 K,精炼气温度373 K,精炼气流速2 L/min作为最优吹气精炼条件时,冶金级硅熔体中的磷元素质量分数由94×10-6降低到11×10-6。表明吹气精炼是一种有效的去除冶金级硅中磷的方法。     

甲醛在nano-Pt/GC电极上的电催化氧化研究

应用循环伏安法制备了nano-Pt/GC电极,并用SEM和电极在H2SO4中的循环伏安曲线对其进行了表征。结果表明,该方法制备的电极表面铂粒子分布较为均匀,粒径大小约为140nm,电极具有较大比表面积。电化学实验表明,该电极对甲醛电氧化的催化活性明显好于铂片电极。修饰电极的催化活性与铂粒子的沉积条件有关,铂微粒在电极表面的最佳沉积条件为循环次数100次和沉积速度5mV/s。     

轻集料混凝土多孔砖砌体基本力学性能试验研究

对在夏热冬冷地区应用达到自保温体系要求的轻集料混凝土多孔砖砌体的基本力学性能进行试验研究,并通过试验分析了块体高度、试件厚度及砌筑形式对砌体抗压强度的影响.试验结果表明,此种自保温墙材可应用于承重结构.     

A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy

BB-10010 is a variant of the human form of macrophage inflammatory protein-1alpha (MIP-1alpha), which has been shown in mice to block the entry of hematopoietic stem cells into S-phase and to increase their self-renewal capacity during recovery from cytotoxic damage. Its use may constitute a novel approach for protecting the quality of the stem cell population and its capacity to regenerate after periods of cytotoxic treatment. Thirty patients with locally advanced or metastatic breast cancer were entered into the first randomized, parallel group controlled phase II study. This was designed to evaluate the potential myeloprotective effects of a 7-day regimen of BB-10010 administered to patients receiving six cycles of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) chemotherapy. Patients were randomized, 10 receiving 100 microgram/kg BB-10010, 11 receiving 30 microgram/kg BB-10010, and nine control patients receiving no BB-10010. BB-10010 was well-tolerated in all patients with no severe adverse events related to the drug. Episodes of febrile neutropenia complicated only 4% of the treatment cycles and there was no difference in incidence between the treated and nontreated groups. Studies to assess the generation of progenitor cells in long-term bone marrow cultures were performed immediately preceding chemotherapy and at the end of six dosing cycles in 18 patients. Circulating neutrophils, platelets, CD 34(+) cells, and granulocyte/macrophage colony-forming cell (GM-CFC) levels were determined at serial time points in cycles 1, 3, and 6. The results showed similar hemoglobin and platelet kinetics in all three groups. On completion of the six treatment cycles, the average pretreatment neutrophil levels were reduced from 5.3 to 1.7 x 10(9)/L in the control patients and from 4.3 to 1.9 and 4.5 to 2.5 x 10(9)/L in the 30/100 microgram/kg BB-10010 groups, respectively. Relative to their pretreatment values, 50% of the patients receiving BB-10010 completed the treatment with neutrophil values significantly higher than any of the controls (P = .02). Mobilization of GM-CFC was enhanced by BB-10010 with an additional fivefold increase over that generated by chemotherapy alone, giving a maximal 25-fold increase over pretreatment values. Bone marrow progenitor assays before and after this standard regimen of chemotherapy indicated little long-term cumulative impairment to recovery from chemotherapy. Despite the limited cumulative damage to the bone marrow, which may have minimized the protective value of BB-10010 during this regimen of chemotherapy, better recovery of neutrophils in the later treatment cycles with BB-10010 was indicated in a number of patients.